2-piperidone has been researched along with Liver Steatosis in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Baik, SH; Choi, DS; Choi, KM; Hong, HC; Hwang, HJ; Jung, TW; Kim, BH; Kim, NH; Kim, SG; Seo, JA; Yoo, HJ | 1 |
Choi, SH; Lee, CK; Lee, IK; Leem, J; Park, KG; Park, S | 1 |
2 other study(ies) available for 2-piperidone and Liver Steatosis
Article | Year |
---|---|
A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression.
Topics: AMP-Activated Protein Kinases; Animals; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Fatty Liver; Hep G2 Cells; Humans; Insulin Resistance; Intercellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; Mice; Mice, Inbred C57BL; Piperidones; Pyrimidines | 2015 |
Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice.
Topics: Adipocytes; Animals; Diet, Western; Fatty Liver; Fibrosis; Hypercholesterolemia; Hypertrophy; Inflammation; Insulin Resistance; Liver; Male; Metabolic Syndrome; Mice; Piperidones; Pyrimidines; Subcutaneous Fat; Uncoupling Protein 1; Weight Gain | 2017 |